NGL Fine-Chem Limited
Established in 1981, NGL Fine-Chem Limited manufacturers and markets APIs, Intermediates and Finished Dosage forms for human and animal pharmaceutical product. It caters to various Indian and global companies with high quality and reliable products.
What NGL files
- Others47
- Investor Meet21
- Board Meeting8
- PPTs7
- Important7
- Credit Ratings5
NGL Fine-Chem delivered a strong Q1FY27, sustaining demand momentum with robust volumes. Revenue from operations jumped 33.57% year-on-year to ₹139.16 Cr, and Profit After Tax (PAT) surged 99.09% year-on-year to ₹18.40 Cr. Animal APIs remain the core, contributing 95% of revenue. EBITDA margin improved to 16.73% (+620 bps YoY). The...
NGL Fine-Chem delivered a strong Q4FY26, with revenue from operations jumping 57.13% YoY to ₹149.23 Cr and PAT soaring to ₹13.49 Cr. For the full FY26, revenue grew 36.03% to ₹500.95 Cr, and PAT surged 127.83% to ₹48.13 Cr, with EBITDA margin improving to 14.51%. This robust performance was driven...
NGL Fine-Chem delivered a strong Q3FY26, with revenue growing 43.11% YoY to ₹127.51 Cr, driven by higher volumes. Profitability significantly improved, with EBITDA surging 337.81% YoY to ₹22.31 Cr (17.50% margin) and PAT up 1,129.12% YoY to ₹15.69 Cr, due to easing raw material costs and operational efficiencies. Animal APIs...
Here is the summary of the attached file: **1. Financial Highlights:** NGL Fine-Chem's Q1FY26 revenue hit ₹104.19 Cr (+14.8% YoY). EBITDA sharply rebounded to ₹10.97 Cr (+73.64% QoQ), boosting margins to 10.53%. PAT of ₹9.24 Cr was flat YoY but significantly up QoQ. **2. Strategic Initiatives & Growth Drivers:** A...
1. Financial Highlights: Revenue rose 8.73% YoY to ₹368.26 Cr for FY25. EBITDA slipped 36.4% to ₹33.87 Cr, with margins down 653 bps to 9.2%. Profit after tax dropped 48.9% to ₹21.12 Cr, pressured by operating challenges and geopolitical issues. Long-term debt increased to ₹25.34 Cr, short-term debt to ₹47.82...